SIGMA-SYSTEMS
2.5.2017 11:02:08 CEST | Business Wire | Press release
Sigma Systems, a global leader in catalog-driven software, has appointed Catherine Michel as Chief Technology Officer (CTO).
Michel previously served as Chief Strategy Officer (CSO) on Sigma’s leadership team, and currently sits on the TM Forum Executive Committee, has been named as one of the most powerful people in the telecoms industry by Global Telecoms Business, and is a public advocate and mentor for women in telco and IT. As Sigma’s Chief Technology Officer, Catherine is responsible for the company's product portfolio and strategy.
“Catherine is a globally respected member of the IT and communications technology community, and we are very fortunate to have her on the Sigma team. She has an excellent track record of innovation within the software development arena and is a highly strategic thinker. Catherine has been vital in driving Sigma’s product portfolio forward, and will continue to do so in her new role in the coming months and years. Catherine is a key spokesperson for the company at events and technology forums across the globe,” said Tim Spencer, Sigma’s President and CEO.
Prior to her roles at Sigma, Michel was the founder and CTO of Tribold, where she was the principal architect of the company's products and solutions portfolio. Tribold was acquired by Sigma in 2013. Prior to co-founding Tribold, she was a senior executive in Accenture's Communications and High Tech practice, devising and delivering business strategy and large-scale B/OSS solutions globally.
“Sigma is on the cutting edge of delivering technology solutions that enable operators to truly transform into agile digital service providers,” observed Michel. “I continue to be excited about the position we’ve achieved in the market and the opportunities ahead of us.”
Catherine will be speaking at TM Forum Live! in Nice with Sigma customer Windstream. The joint presentation will outline how Windstream developed, governed and executed a widespread digital transformation program in parallel with a major acquisition and SDN deployment. As a key strategic partner, Sigma is supporting Windstream’s transition to an agile delivery organization with the adoption of catalog-driven Agile B/OSS. Sigma’s portfolio is designed to support CSPs like Windstream to embrace digital innovation and enable the rapid launch and fulfilment of new products and services without entirely dismantling existing legacy systems.
Presentation Details:
May 15th
, 11:15am
TM Forum
Live!
Palais des Congrès Acropolis, Nice, France
About Sigma Systems (
sigma-systems.com
or Twitter @SigmaSystems)
Sigma Systems is a global leader in
catalog-driven software solutions for communications, media, and
high-tech companies. It serves over 80 customers in 40 countries with
its award-winning products.
The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management and Provisioning products, which can be deployed in the cloud or on-premise. Sigma utilizes an agile approach to implementing its B/OSS products for its customers.
Sigma has offices in North and South America, Europe and Asia, with technology and integration partners in over 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005185/en/
Contact:
Sigma Systems
Noor Manji, 416-943-9696
Manager, Corporate
Communications
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom